Physician profile
Howard Amiel
NPI 1306964317
$2,687.10
in general payments reported to CMS, 2019-2025
18 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $279 · 2021: $170 · 2022: $206 · 2023: $258 · 2024: $574 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.97 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $904.26 | 2019-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Glaukos Corporation | $532.78 | 2021-2025 | Idose, Photrexa Viscous and Photrexa, Photrexa Cross-Linking Kit |
| Rxsight INC | $333.72 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $205.45 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Abbvie INC. | $119.73 | 2024-2025 | |
| Ocular Therapeutix, INC. | $109.58 | 2021-2025 | Dextenza |
| Dompe US, INC. | $94.58 | 2022-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $54.43 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.14 | 2019-2021 | |
| Biotissue Holdings INC. | $47.64 | 2022-2023 | |
| Harrow Eye, LLC | $46.66 | 2023-2025 | Iheezo, Vevye |
| Carl Zeiss Meditec USA, INC. | $42.02 | 2022 | |
| Allergan, INC. | $35.63 | 2020-2022 | |
| Rayner Intraocular Lenses Limited | $27.75 | 2024 | Rayone Spheric, Rayone Aspheric, Rayner Cataract Set 1 |
| Travere Therapeutics, INC. | $23.90 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $22.78 | 2025 | |
| Bausch & Lomb Americas INC. | $21.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Amiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.